Tolterodine

Drugs

Volumn 55, Issue 6, 1998, Pages 813-820

  Hills, C J ^a   Winter, S A ^a   Balfour, J A ^a   Abrams, P ^a   Brenner, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; RECEPTOR SUBTYPE; TOLTERODINE;

ARTICLE; BLADDER; BLADDER CONTRACTION; BLADDER DISEASE; CLINICAL TRIAL; HUMAN; LONG TERM CARE; META ANALYSIS; MICTURITION; ORAL DRUG ADMINISTRATION; SALIVARY GLAND; SALIVATION; URINE INCONTINENCE; URINE VOLUME; XEROSTOMIA;

EID: 0031804227     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855060-00008     Document Type: Article

References (37)

1. 1. TM Thomas KR Plymatt J Blannin 1980 Prevalence of urinary incontinence BMJ 81 1242 5 Thomas TM, Plymatt KR, Blannin J, et al. Prevalence of urinary incontinence. BMJ 1980; 81: 1242–5
2. 2. LD Cardozo SL Stanton 1980 Genuine stress incontinence and detrusor instability — a review of 200 patients Br J Obstet Gynaecol 87 184 90 7387918 10.1111/j.1471-0528.1980.tb04515.x 1:STN:280:DyaL3c3itV2lsQ%3D%3D Cardozo LD, Stanton SL. Genuine stress incontinence and detrusor instability — a review of 200 patients. Br J Obstet Gynaecol 1980; 87: 184–90
3. 3. KE Andersson 1988 Current concepts in the treatment of disorders of micturition Drugs 35 477 94 3292211 10.2165/00003495-198835040-00006 1:STN:280:DyaL1c3ntFajtA%3D%3D Andersson KE. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35: 477–94
4. 4. L Nilvebrant K-E Andersson P-G Gillberg 1997 Tolterodine — a new bladder-selective antimuscarinic agent Eur J Pharmacol 327 195 207 9200560 10.1016/S0014-2999(97)89661-6 1:CAS:528:DyaK2sXjtlWntrw%3D Nilvebrant L, Andersson K-E, Gillberg P-G, et al. Tolterodine — a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997 May 30; 327: 195–207
5. 5. L Nilvebrant B Hallen G Larsson 1997 Tolterodine — a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data Life Sci 60 1129 36 9121357 10.1016/S0024-3205(97)00057-X 1:CAS:528:DyaK2sXhvFSqt7g%3D Nilvebrant L, Hallen B, Larsson G. Tolterodine — a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129–36
6. 6. L Nilvebrant S Sundquist P-G Gillberg 1996 Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo Neurourol Urodyn 15 310 1 Nilvebrant L, Sundquist S, Gillberg P-G. Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo. Neurourol Urodyn 1996; 15: 310–1
7. 7. L Nilvebrant P-G Gillberg B Sparf 1997 Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine Pharmacol Toxicol 81 169 72 9353847 10.1111/j.1600-0773.1997.tb02064.x 1:CAS:528:DyaK2sXmvVKltLw%3D Nilvebrant L, Gillberg P-G, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169–72
8. 8. H Naerger CH Fry L Nilverbrant 1995 Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders Neurourol Urodyn 14 524 6 Naerger H, Fry CH, Nilverbrant L. Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders. Neurourol Urodyn 1995; 14: 524–6
9. 9. N Brynne MMS Stahl B Hallén 1997 Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity Int J Clin Pharmacol Ther 35 287 95 9247842 1:CAS:528:DyaK2sXkslyqsb4%3D Brynne N, Stahl MMS, Hallén B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997 Jul; 35: 287–95
10. 10. MMS Stahl B Ekström B Sparf 1995 Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity Neurourol Urodyn 14 6 647 55 8750383 10.1002/nau.1930140606 1:CAS:528:DyaK28XhtFyrtbo%3D Stahl MMS, Ekström B, Sparf B, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995; 14(6): 647–55
11. 11. Olsson B, Arnberg H, Petersson R. Dose proportionality of tolterodine. An open, randomized, single-dose cross over study in healthy volunteers. Pharmacia & Upjohn document 9600247, 1996
12. 12. Lönnebo A, Brynne N, Holgersson M, et al. Pharmacokinetic report. Tolerability and pharmacokinetic effects of Kabi 2234 (tolterodine L-tartrate) in elderly: a randomized double-blind study in healthy volunteers. Pharmacia & Upjohn document 9400315, 1994
13. 13. Olsson B. Analysis of sex differences in the pharmacokinetics of tolterodine. An analysis of data from three single-dose studies (CTN 95-OATA-022; 95-OATA-029; 95-OATA-028) in fasting healthy volunteers. Pharmacia & Upjohn document 9600485, 1996
14. 14. Karlmark B, Nordgren L, Lebel L. Electrophysiological heart effects of repeated i.V. atropine injections, repeated oral dosage of Kabi 2234 and placebo to healthy human volunteers in a parallel group design. Pharmacia & Upjohn document 930019,1993
15. 15. Brynne N, Dalén P, Alván G, et al. The influence of CYP2D6 polymorphism on the pharmacokinetics and dynamics of tolterodine [in press]. Clin Pharmacol Ther 1998
16. 16. Gozzi P, Påhlman I. Serum protein binding of tolterodine and its 5-hydroxymethyl metabolite in different species [abstract]. 6th ISSX 1997 Jun 30: 227
17. 17. Postlind H, Danielson A, Lindgren A, et al. Tolterodine, a novel muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes [in press]. Drug Metab Dispos 1998
18. 18. Hallén B. Summary and evaluation of pharmacokinetics and clinical pharmacology. Pharmacia & Upjohn document 9600588, 1996
19. 19. Rahimy MH, Narang PK, Scheinman S. A phase I, open label, safety and pharmacokinetic study of tolterodine in patients with hepatic cirrhosis. Pharmacia & Upjohn document 9600328, 1996
20. 20. N Brynne B Apéria A Åberg-Wistedt 1997 Inhibition of tolterodine metabolism by fluoxetine with minor change in antimuscarinic activity [abstract] Eur J Clin Pharmacol 52 A130 Brynne N, Apéria B, Åberg-Wistedt A, et al. Inhibition of tolterodine metabolism by fluoxetine with minor change in antimuscarinic activity [abstract]. Eur J Clin Pharmacol 1997; 52 Suppl: A130
21. 21. Rahimy MH, Fleishaker JC, Narang PK. Aphase I, randomized, double-blind, placebo-controlled, kinetic-dynamic and safety drug interaction study of tolterodine and warfarin in healthy volunteers. Pharmacia & Upjohn document 9600327, 1996
22. 22. Olsson B, Landgren B-M, Selinus I. Influence of tolterodine on the pharmacokinetics of Neovletta, an oral contraceptive. An open, randomized, multiple-dose cross-over study in healthy volunteers. Pharmacia & Upjohn document 9600483, 1996
23. 23. Abrams P, Jackson S, Mattiasson A, et al. A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia [abstract]. 26th Annual Meeting of the International Continence Society, 1996 Aug 27–30, Athens
24. 24. Van Kerrebroeck PhEVA, Amarenco G, Thiiroff JW, et al. Doseranging study of tolterodine in patients with detrusor hyperreflexia [in press]. Neurourol Urodyn 1998
25. 25. L Rentzhog SL Stanton L Cardozo 1997 Efficacy and safety of tolterodine in patients with detrusor instability: a doseranging study Br J Urol 81 42 8 Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a doseranging study. Br J Urol 1997; 81: 42–8
26. 26. Köhlerstrand E, Sander H, Lebel L, et al. A phase II randomised, double-blind, placebo-controlled, parallel group, dose ranging multicentre study of the safety and efficacy of tolterodine in patients with detrusor instability. Pharmacia & Upjohn document 9600436,1996
27. 27. Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of urge incontinence. Analysis of the pooled phase II efficacy and safety data [abstract]. 26th Annual Meeting of the International Continence Society; 1996; Aug 27–30, Athens
28. 28. U Jonas K Höfner H Madersbacher 1997 Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation World J Urol 15 144 51 9144906 10.1007/BF02201987 1:CAS:528:DyaK2sXjt1Gku7w%3D Jonas U, Höfner K, Madersbacher H, et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997 Apr; 15: 144–51
29. 29. K Moore R Millard P Dwyer 1997 A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia [abstract] Int Urogynecol J 8 S129 Moore K, Millard R, Dwyer P, et al. A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia [abstract]. Int Urogynecol J 1997; 8: S129
30. 30. Malone-Lee J, Maugourd MF, Walsh B. Clinical efficacy and safety of tolterodine vs placebo in elderly patients with unstable bladder: a randomised, double-blind, multinational study [abstract]. 27th Annual Meeting of the International Continence Society, 1997; Sep 23–26, Yokohama
31. 31. P Abrams RN Freeman C Anderström 1997 Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability [abstract] J Urol 157 103 Abrams P, Freeman RN, Anderström C, et al. Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability [abstract]. J Urol 1997 Apr; 157 Suppl.: 103
32. 32. H Drutz RA Appell 1997 Clinical efficacy and safety of tolterodine vs oxybutynin and placebo in patients with unstable bladder [abstract] Acta Obstet Gynecol Scand 76 24 Drutz H, Appell RA. Clinical efficacy and safety of tolterodine vs oxybutynin and placebo in patients with unstable bladder [abstract]. Acta Obstet Gynecol Scand 1997; 76: 24
33. 33. P Kerrebroeck Van G Serment E Dreher 1997 Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder Neurourol Urodyn 16 478 9 Van Kerrebroeck PhEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997; 16: 478–9
34. 34. RA Apell 1997 Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis Urology 50 6A 90 6 10.1016/S0090-4295(97)00599-2 Apell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 Suppl. 6A: 90–6
35. 35. Hallén B, Nordgren L, Landelius J, et al. Tolterodine and terodiline — ECG safety profiles [abstract]. 27th Annual Meeting of the International Continence Society, 1997; Sept 23–26, Yokohama
36. 36. Edholm M, Olofsson S, Dash CH, et al. The effect of the combination of tolterodine and thiazides on the ECG. A double-blind, placebo-controlled, randomized, two-period, cross-over study. Pharmacia & Upjohn document 9700161, 1997
37. 37. Anonymous. Detrusitol TM International Monograph. Adis International Limited, Chester, 1998